# Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

> **NCT00005870** · PHASE3 · UNKNOWN · sponsor: **Astex Pharmaceuticals, Inc.**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** fluorouracil
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** mitomycin C
- **DRUG:** rubitecan

## Key facts

- **NCT ID:** NCT00005870
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005870, "Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00005870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*